in the evaluation of REITs, many of which present FFO when
reporting their results. FFO is intended to exclude GAAP historical cost
depreciation and amortization of real estate and related assets, which
assumes that the value of real estate assets diminishes ratably over time.
Historically, however, real estate values have risen or fallen with market
conditions. Because FFO excludes depreciation and amortization unique to
real estate, gains and losses from property dispositions and extraordinary
items, it provides an operating performance measure that, when compared
year over year, reflects the impact to operations from trends in occupancy
rates, rental rates, operating costs, development activities and interest
costs, providing perspective not immediately apparent from net income. We
compute FFO in accordance with standards established by the Board of
Governors of the National Association of Real Estate Investment Trusts, or
NAREIT, in its March 1995 White Paper (as amended in November 1999 and
April 2002). As defined by NAREIT, FFO represents net income (computed in
accordance with GAAP), excluding gains (or losses) from sales of property,
plus real estate related depreciation and amortization (excluding
amortization of loan origination costs) and after adjustments for
unconsolidated partnerships and joint ventures. Our computation may differ
from the methodology for calculating FFO utilized by other equity REITs
and, accordingly, may not be comparable to such other REITs. Further, FFO
does not represent amounts available for management's discretionary use
because of needed capital replacement or expansion, debt service
obligations, or other commitments and uncertainties. FFO should not be
considered as an alternative to net income (loss) (computed in accordance
with GAAP) as an indicator of our financial performance or to cash flow
from operating activities (computed in accordance with GAAP) as an
indicator of our liquidity, nor is it indicative of funds availab
'/>"/>SOURCE BioMed Realty Trust, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine news :1.
Response Biomedical appoints S. Wayne Kay Chief Executive Officer2.
Biomedtex Inc. Announces A. Marc Rocca as President and CEO3.
Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?4.
Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors5.
BioMed Realty Trust to Report 2007 Third Quarter Results6.
BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant7.
Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange8.
Universal Health Realty Income Trust Announces Dividend9.
Healthcare Realty Trust Announces Public Offering of Common Stock10.
New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 811.
AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care